… is an American posting. It gives updates of new and trial drugs, reports from conferences and suchlike. I find it very interesting and I am subscribed to get their news by e-mail.
This is their latest post… you might find it worth subscribing to:
[b]The Myeloma Beacon
May 30, 2012 11:14 am
The Myeloma Beacon is brought to you in part by:
Memorial Sloan-Kettering Cancer Center
News ยป
Beacon NewsFlashes – May 30, 2012[/b]
by The Myeloma Beacon Staff
INNO-206 Shows Activity Against Myeloma ? Results of a preclinical study show that the investigational drug INNO-206 inhibits blood vessel formation and reduces cell growth in myeloma cell lines. The drug showed these effects when tested alone; additionally it enhanced the efficacy of Velcade (bortezomib) when tested in combination. INNO-206 is a derivative of the chemotherapy agent doxorubicin (Adriamycin). This study also showed that INNO-206 was safer in mice than doxorubicin and therefore could be administered at higher doses. For information, please see the study in Clinical Cancer Research (abstract).
TRAIL-Doxorubicin Combination May Eradicate Myeloma Cells ? Results of a preclinical study show that a combination of doxorubicin and TRAIL, a protein that induces cell death, was able to eradicate myeloma cell lines. In particular, the TRAIL-doxorubicin combination successfully eliminated cells that are implicated in tumor initiation as well as tumor growth. According to the study investigators, these findings offer a promising new approach to finding a cure for multiple myeloma. For more information, please see the study in PloS One.
Relatives Of Multiple Myeloma Patients Have Increased Risk Of MGUS ? Results of a study conducted at the Mayo Clinic indicate that first-degree relatives of multiple myeloma patients are 3.4 times as likely to develop light-chain monoclonal gammopathy of undetermined significance (MGUS) compared to the general population. A previous study also showed that these relatives are at an increased risk of developing heavy-chain MGUS. For more information, please see the study in the British Journal of Hematology (abstract).
IMF Myeloma Workshop For Patients And Families ? The International Myeloma Foundation (IMF) will be hosting a workshop for multiple myeloma patients and their families on June 23 in Milwaukee, WI. Dr. Ayman Saad from the Medical College of Wisconsin, Dr. Natalie Callander from the University of Wisconsin School of Medicine, and nurse Tiffany Richards from the MD Anderson Cancer Center in Houston will speak about topics including treatment options, managing side effects, and local clinical trials.
BADGER 12 years, 7 months ago.
